NeuroTech AI

Executive Summary

NeuroTech AI is a San Francisco-based company at the intersection of neuroscience and artificial intelligence, developing AI-powered diagnostic tools for neurological and psychiatric disorders. By analyzing multimodal data—including imaging, speech, and wearables—the platform identifies digital biomarkers for early detection and disease monitoring, with a focus on Alzheimer’s disease and major depressive disorder. Founded in 2020, the company addresses a critical need for objective, scalable diagnostics in mental health and neurodegeneration, where traditional methods often rely on subjective assessments or invasive procedures. Its technology has the potential to improve patient outcomes, reduce healthcare costs, and accelerate clinical trials.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for Alzheimer’s diagnostic platform75% success
• Q4 2026Strategic partnership with a top-tier pharmaceutical company for depression biomarker validation65% success
• Q3 2026Series D funding round exceeding $150 million80% success